PDXDC1 (pyridoxal dependent decarboxylase domain containing 1) encodes a putative enzyme that may metabolize catecholamine neurotransmitters and appears to play significant roles in neurodevelopment and metabolic processes 1. The protein localizes to the Golgi apparatus and participates in cadherin binding interactions. Functionally, PDXDC1 modulates prepulse inhibition (PPI) of acoustic startle response, a schizophrenia endophenotype, with hippocampal expression levels inversely correlated with PPI performance across mouse strains 1. Experimental suppression of PDXDC1 in the hippocampus increased PPI by 70%, suggesting it may represent a potential therapeutic target for schizophrenia 1. The gene shows clinical relevance across multiple conditions: it is associated with ADHD risk during early brain development 2, contributes to metabolic syndrome and inflammatory marker networks 3, and serves as a biomarker for acute rejection in kidney transplantation 4. Additionally, PDXDC1 influences circulating phospho- and sphingolipid concentrations 5, and copy number variations affecting this gene at chromosome 16.11 are associated with cardiac left-right patterning defects and congenital heart disease 6. These diverse associations suggest PDXDC1 plays important roles in neurodevelopment, metabolism, and cardiovascular development.